BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32025869)

  • 1. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
    Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
    Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
    Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
    Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
    Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging features to distinguish posterior fossa ependymoma subgroups.
    Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
    Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
    Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis and prognostic factors in posterior fossa ependymomas in children and adolescents.
    Costa MDSD; Torres Soares C; Dastoli PA; Mendonça Nicácio J; de Seixas Alves MT; Chen MJ; Cappellano AM; Saba da Silva N; Cavalheiro S
    J Neurosurg Pediatr; 2023 Oct; 32(4):404-412. PubMed ID: 37410603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Molecular Subgroups on Prognosis and Survival Outcomes in Posterior Fossa Ependymomas: A Retrospective Study of 412 Cases.
    Wang B; Yan M; Han B; Liu X; Liu P
    Neurosurgery; 2024 Mar; ():. PubMed ID: 38529997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
    Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
    J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
    Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
    J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supratentorial extraventricular ependymomas: A retrospective study focused on long-term outcomes and prognostic factors.
    Wang M; Zhang R; Liu X; Li D; Qiu C; Zhao P; Zuo Y; Zhang P; Wang J; Sun H
    Clin Neurol Neurosurg; 2018 Feb; 165():1-6. PubMed ID: 29253745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.
    Zapotocky M; Beera K; Adamski J; Laperierre N; Guger S; Janzen L; Lassaletta A; Figueiredo Nobre L; Bartels U; Tabori U; Hawkins C; Urbach S; Tsang DS; Dirks PB; Taylor MD; Bouffet E; Mabbott DJ; Ramaswamy V
    Cancer; 2019 Jun; 125(11):1867-1876. PubMed ID: 30768777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in intracranial ependymomas in children.
    Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
    J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Jenseit A; Camgöz A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
    Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
    Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Massimino M; Barretta F; Modena P; Witt H; Minasi S; Pfister SM; Pajtler KW; Antonelli M; Gandola L; Luisa Garrè M; Bertin D; Mastronuzzi A; Mascarin M; Quaglietta L; Viscardi E; Sardi I; Ruggiero A; Pollo B; Buccoliero A; Boschetti L; Schiavello E; Chiapparini L; Erbetta A; Morra I; Gessi M; Donofrio V; Patriarca C; Giangaspero F; Johann P; Buttarelli FR
    Neuro Oncol; 2021 May; 23(5):848-857. PubMed ID: 33135735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles.
    Zhang M; Wang E; Yecies D; Tam LT; Han M; Toescu S; Wright JN; Altinmakas E; Chen E; Radmanesh A; Nemelka J; Oztekin O; Wagner MW; Lober RM; Ertl-Wagner B; Ho CY; Mankad K; Vitanza NA; Cheshier SH; Jacques TS; Fisher PG; Aquilina K; Said M; Jaju A; Pfister S; Taylor MD; Grant GA; Mattonen S; Ramaswamy V; Yeom KW
    Neuro Oncol; 2022 Jun; 24(6):986-994. PubMed ID: 34850171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.